[go: up one dir, main page]

MX2018002997A - Composicion para mantener la dominancia de lactobacillus. - Google Patents

Composicion para mantener la dominancia de lactobacillus.

Info

Publication number
MX2018002997A
MX2018002997A MX2018002997A MX2018002997A MX2018002997A MX 2018002997 A MX2018002997 A MX 2018002997A MX 2018002997 A MX2018002997 A MX 2018002997A MX 2018002997 A MX2018002997 A MX 2018002997A MX 2018002997 A MX2018002997 A MX 2018002997A
Authority
MX
Mexico
Prior art keywords
compositions
growth
therapeutic agent
lactobacilli
lactobacillus
Prior art date
Application number
MX2018002997A
Other languages
English (en)
Other versions
MX390741B (es
Inventor
William Koenig David
Ann Vongsa Rebecca
Li Jingru
Adrienne Peed Lindsay
Francina Joyner Cheryce
Daniel Bartell Ryan
Original Assignee
Kimberly Clark Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58424235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018002997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kimberly Clark Co filed Critical Kimberly Clark Co
Publication of MX2018002997A publication Critical patent/MX2018002997A/es
Publication of MX390741B publication Critical patent/MX390741B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/719—Pullulans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona composiciones y formulaciones capaces de mantener o promover el crecimiento de ciertas cepas de Lactobacilli spp. Las composiciones y formulaciones generalmente comprenden solamente un agente terapéutico único seleccionado del grupo que consiste en isomaltulosa, maltitol, pululano, maltotriosa, 2-desoxi-D-ribosa, 1-cestosa y erlosa. El agente terapéutico único es la única fuente de carbono para la bacteria cuando se administra a un usuario. A pesar de comprender solamente un agente terapéutico único se ha demostrado que las composiciones promueven el crecimiento y mantenimiento de lactobacilos beneficiosos e inhiben eficazmente el crecimiento de patógenos asociados con las infecciones urogenitales. Como tal la administración de las composiciones mantienen un equilibrio saludable de la microflora en el área urogenital.
MX2018002997A 2015-09-29 2015-09-29 Composicion para mantener la dominancia de lactobacillus. MX390741B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/052951 WO2017058174A1 (en) 2015-09-29 2015-09-29 Composition for maintaining loctobacillus dominance

Publications (2)

Publication Number Publication Date
MX2018002997A true MX2018002997A (es) 2018-05-07
MX390741B MX390741B (es) 2025-03-21

Family

ID=58424235

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002997A MX390741B (es) 2015-09-29 2015-09-29 Composicion para mantener la dominancia de lactobacillus.

Country Status (8)

Country Link
US (2) US20180256615A1 (es)
EP (2) EP3831391A1 (es)
KR (2) KR20180054653A (es)
CN (1) CN108135919B (es)
AU (1) AU2015410634B2 (es)
MX (1) MX390741B (es)
RU (1) RU2723015C2 (es)
WO (1) WO2017058174A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108235682A (zh) 2015-09-29 2018-06-29 金伯利-克拉克环球有限公司 用于维护微生物群落的健康平衡的协同组合物
BR112019015239A2 (pt) 2017-02-28 2020-04-14 Kimberly Clark Co composição, e, método para manter um equilíbrio de microflora saudável na área urogenital de um paciente com necessidade do mesmo.
KR102116686B1 (ko) 2020-01-02 2020-05-29 주식회사 쎌바이오텍 성장 인자를 포함하는 유산균 증식 촉진용 조성물
KR20230047399A (ko) * 2020-07-23 2023-04-07 킴벌리-클라크 월드와이드, 인크. 방광 건강 개선을 위한 방광 마이크로바이옴 조절 방법
JP2023084325A (ja) * 2021-12-07 2023-06-19 株式会社希松 デーデルライン桿菌の増殖促進剤および微生物選択的増殖促進剤
AU2023315957A1 (en) * 2022-07-29 2025-03-06 Kimberly-Clark Worldwide, Inc. Methods and compositions related to prebiotic formulations useful in promoting urogenital health

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4326053A (en) 1978-12-04 1982-04-20 Merck & Co., Inc. Polysaccharide S-60 and bacterial fermentation process for its preparation
KR830002802B1 (ko) 1978-12-04 1983-12-16 제임스 에프 · 너우톤 박테리아 발효에 의한 다당류 s-60의 제조방법
US4377636A (en) 1979-06-08 1983-03-22 Merck & Co., Inc. Polysaccharide S-60 and bacterial fermentation process for its preparation
US4385123A (en) 1979-06-08 1983-05-24 Merck & Co., Inc. Deacetylated polysaccharide S-60
US4563366A (en) 1983-05-31 1986-01-07 Merck & Co., Inc. Non-heated gellan gum gels
CN1211189A (zh) * 1996-02-14 1999-03-17 普罗克特和甘保尔公司 含衍自杜鹃花科植物的物质和乳酸菌生长因子的,用于泌尿生殖系统和肠道疾病的组合物
US6964949B2 (en) * 2000-05-24 2005-11-15 Shanghai Jiao Da Onlly Co., Ltd. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
CN1562049A (zh) 2004-04-02 2005-01-12 聂四平 低聚果糖在制备治疗及预防阴道炎药中的应用
FR2874825B1 (fr) * 2004-09-08 2006-12-08 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
RU2409368C2 (ru) * 2005-04-27 2011-01-20 Шэньчжэнь Флора Байотекнолоджи Лимитед Композиция и способ регуляции и поддержания бактериальной микрофлоры и кислотности влагалища
KR20080059581A (ko) * 2005-10-13 2008-06-30 메이지 세이카 가부시키가이샤 장내 플로라 개선용 조성물
CN101411714A (zh) 2007-10-15 2009-04-22 杜军 治疗阴道炎的化学物质
FI122247B (fi) * 2009-08-12 2011-10-31 Vetcare Oy Probioottinen valmiste koiran maha- ja suolistokanavassa ilmenevien häiriöiden ennaltaehkäisemiseksi tai hoitamiseksi
RU2473347C1 (ru) * 2011-11-09 2013-01-27 Сергей Константинович Панюшин Композиция пребиотиков для нормализации микрофлоры организма
CN102870987B (zh) * 2012-09-19 2013-12-11 广州立达尔生物科技股份有限公司 一种用于改善幼龄动物肠道发育的绿色饲料添加剂
CN110840903B (zh) * 2014-03-13 2021-08-31 深圳优丽康生物技术有限公司 异麦芽酮糖在制备选择性促进乳杆菌生长用组合物上的用途及该组合物

Also Published As

Publication number Publication date
EP3355894A4 (en) 2019-05-29
US20180256615A1 (en) 2018-09-13
MX390741B (es) 2025-03-21
EP3355894B1 (en) 2024-04-24
EP3355894A1 (en) 2018-08-08
RU2723015C2 (ru) 2020-06-08
EP3831391A1 (en) 2021-06-09
AU2015410634B2 (en) 2021-09-30
RU2018111436A (ru) 2019-10-01
WO2017058174A1 (en) 2017-04-06
KR20230165382A (ko) 2023-12-05
KR20180054653A (ko) 2018-05-24
CN108135919B (zh) 2024-06-18
AU2015410634A1 (en) 2018-04-12
CN108135919A (zh) 2018-06-08
RU2018111436A3 (es) 2019-10-01
US20220257622A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
MX2018002997A (es) Composicion para mantener la dominancia de lactobacillus.
PH12017502001A1 (en) Amido-substituted cyclohexane derivatives
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
PE20151786A1 (es) Compuestos heterociclicos y sus usos
TN2015000371A1 (en) Substituted imidazopyridazines
CO2020012954A2 (es) Siloxanos biocompatibles para formulación de microorganismos
PH12016501807A1 (en) Novel compounds
PH12017501133A1 (en) Pyrazolopyridinamines
UY37577A (es) Dihidroimidazopiridindionas sustituidas
MX2016000163A (es) Pirazolpiridinas sustituidas.
UY35848A (es) Tienopirimidinas
MX2018005489A (es) Agente antimicrobiano que comprende xantohumol y su uso en productos alimenticios.
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
CO2019006652A2 (es) Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
BR112021026471A2 (pt) Formulações de dose sólida para a liberação sem agulha
BR112014015193A2 (pt) composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico
UY36983A (es) Pirazolopiridinaminas sustituidas
TN2014000091A1 (en) Amino-substituted imidazopyridazines
NZ727233A (en) Stabilized oxymetazoline formulations and their uses